Algert Global’s Coherus Oncology CHRS Stock Holding History

Algert Global’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-18,270	Closed	-$296K	–	429
2020 Q1	$296K	Sell	18,270 -11,469	-39%	-$212K	0.12%	249
2019 Q4	$535K	Sell	29,739 -46,769	-61%	-$863K	0.16%	197
2019 Q3	$1.55M	Buy	+76,508	New	+$1.53M	0.58%	57
2019 Q1	–	Sell	-72,478	Closed	-$656K	–	325
2018 Q4	$656K	Buy	72,478 +42,557	+142%	+$492K	0.18%	184
2018 Q3	$494K	Sell	29,921 -5,312	-15%	-$94.2K	0.11%	248
2018 Q2	$493K	Buy	+35,233	New	+$504K	0.1%	245

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Algert Global's CHRS Position: Q2 2020 in Review

Algert Global sold out of Coherus Oncology (CHRS) in Q2 2020, closing a stake of 18,270 shares — an estimated $296K sold.

Algert Global first reported a position in CHRS in Q2 2018 and held it in 6 quarters. The position peaked at $1.55M in Q3 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2020.

Algert Global reported no remaining Coherus Oncology position as of Q2 2020 after selling out during the quarter.
Algert Global sold 18,270 Coherus Oncology shares in Q2 2020, an estimated $296K.
Algert Global first reported a position in Coherus Oncology in Q2 2018 and held it in 6 quarters.
Algert Global's Coherus Oncology position peaked at $1.55M in Q3 2019.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2020.

Based on Algert Global's 13F filing for Q2 2020, filed 12 Aug 2020.